<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949441</url>
  </required_header>
  <id_info>
    <org_study_id>TH004</org_study_id>
    <nct_id>NCT01949441</nct_id>
  </id_info>
  <brief_title>ToleroMune House Dust Mite (HDM) Tolerability Study</brief_title>
  <official_title>A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Tolerability of ToleroMune House Dust Mite in Subjects With Controlled Asthma and House Dust Mite-Induced Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      House Dust Mites (HDMs) are arachnids that infest bedding, carpet, upholstered furniture and&#xD;
      fabric. Like many other allergens, exposure to HDMA in sensitised patients is associated with&#xD;
      poorer lung function, greater medication requirements and more asthma symptoms as well as&#xD;
      chronic rhinosinusitis symptoms. In contrast to other allergens, there is evidence that HDMA&#xD;
      leads to the development of asthma, in addition to exacerbating pre-existing asthma in&#xD;
      HDM-sensitised patients.&#xD;
&#xD;
      ToleroMune House Dust Mite (TM-HDM), a combination of seven Synthetic Peptide&#xD;
      Immuno-Regulatory Epitopes, is being developed for the treatment of HDM allergy.&#xD;
&#xD;
      This study to assess the tolerability of ToleroMune House Dust Mite in subjects with&#xD;
      controlled asthma and house dust mite-induced rhinoconjunctivitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-centre, randomised, double-blind, placebo-controlled, parallel-group, multiple dose&#xD;
      study to evaluate the tolerability of four intradermal doses of TM-HDM in subjects with&#xD;
      controlled asthma and HDM-induced rhinoconjunctivitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 19 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 and FVC</measure>
    <time_frame>Up to 19 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow Rate</measure>
    <time_frame>Up to 19 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Breathlessness</measure>
    <time_frame>Up to 19 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Exacerbations</measure>
    <time_frame>Up to 19 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Allergic Reactions</measure>
    <time_frame>Up to 19 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection Site Examinations</measure>
    <time_frame>Up to 19 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>ToleroMune HDM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ToleroMune HDM</intervention_name>
    <description>Intradermal injection 1 x 4 administrations 4 weeks apart</description>
    <arm_group_label>ToleroMune HDM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection 1 x 4 administrations 4 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 18-65 years.&#xD;
&#xD;
          -  Asthma controlled by Step 1 or Step 2 treatment as defined by GINA in the four weeks&#xD;
             prior to randomisation.&#xD;
&#xD;
          -  Asthma controlled by Step 1 or Step 2 treatment as defined by GINA in the four weeks&#xD;
             prior to randomisation.&#xD;
&#xD;
          -  No change in asthma controller treatment (dose, frequency) in the four weeks prior to&#xD;
             randomisation.&#xD;
&#xD;
          -  A reliable history consistent with rhinoconjunctivitis on exposure to HDM for at least&#xD;
             1 year that has required symptomatic treatment on at least one occasion during the&#xD;
             year prior to randomisation&#xD;
&#xD;
          -  Positive skin prick test to Dermatophagoides pteronyssinus with an average wheal&#xD;
             diameter at least 5 mm larger than that produced by the negative control.&#xD;
&#xD;
          -  ImmunoCAP® Dermatophagoides pteronyssinus-specific Immunoglobulin E ≥ 0.35 kU/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of life-threatening asthma&#xD;
&#xD;
          -  Asthma exacerbation in the 12 weeks prior to randomisation&#xD;
&#xD;
          -  Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) &lt; 80 % of predicted,&#xD;
             regardless of the cause.&#xD;
&#xD;
          -  Post-bronchodilator FEV1/Forced Vital Capacity ratio of &lt; 0.7.&#xD;
&#xD;
          -  Concurrent respiratory disease that would confound study participation or affect&#xD;
             subject safety.&#xD;
&#xD;
          -  Non-HDM allergy that may significantly interfere with the results of this study.&#xD;
&#xD;
             7. Previous immunotherapy treatment with any HDM allergen for more than 1 month within&#xD;
             5 years prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Topstone Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 4Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDM Allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>ToleroMune HDM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

